Effect of anti-viral therapy for occult hepatitis C virus infection

Alimentary Pharmacology and Therapeutics

Volumn 23, Issue 8, 2006, Pages 1153-1159

  Pardo, M ^a   Lopez Alcorocho J M ^a   Castillo, I ^a   Rodriguez Inigo E ^a   Perez Mota, A ^b   Carreno V ^a,c  

^a Hospital Pardo De Aravaca   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^c NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG EFFECT; DRUG RESPONSE; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER NECROSIS; MALE; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CONFIDENCE INTERVALS; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C; HUMANS; IN SITU HYBRIDIZATION; INTERFERON ALFA-2A; LEUKOCYTES, MONONUCLEAR; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; STATISTICS, NONPARAMETRIC; VIRAL LOAD;

EID: 33646877479     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02886.x     Document Type: Article

References (23)

1. Lauer GM Walker BD. Hepatitis C virus infection. N Engl J Med 2001 345 :41 52.
2. Wong JB McQuillan GM McHutchison JG Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000 90 :1562 9.
3. Davis GL Lau JY Lim HL. Therapy for chronic hepatitis C. Gastroenterol Clin North Am 1994 23 :603 13.
4. Strader DB Wright T Thomas DL Seef LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004 39 :1147 71.
5. Marcellin P Asselah T Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002 36 :S47 56.
6. Yano M Kumada H Kage H, et al. The long term pathological evolution of chronic hepatitis C. Hepatology 1996 23 :1334 40.
7. Nelson DR. The immunopathogenesis of hepatitis C virus infection. Clin Liver Dis 2001 5 :931 53.
8. Castillo I Pardo M Bartolomé J, et al. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 2004 189 :7 14.
9. Pardo M López-Alcorocho JM Rodríguez-Iñigo E Castillo I Carreño V. Comparative study between occult hepatitis C virus infection and chronic hepatitis C. J Viral Hepat 2006 in press.
10. Castillo I Rodríguez-Iñigo E Bartolomé J, et al. Hepatitis C virus replicates in peripheral blood mononuclear cells of patients with occult hepatitis C virus infection. Gut 2005 54 :682 5.
11. Lindsay KL. Introduction to therapy of hepatitis C. Hepatology 2002 36 :S114 20.
12. Lau DT Kleiner DE Ghany MG Park Y Schmid P Hoofnagle JH. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 1998 28 :1121 7.
13. Scheuer PJ Standish RA Dhillon AP. Scoring of chronic hepatitis. Clin Liver Dis 2002 6 :335 47.
14. Kwok S Higuchi R. Avoiding false positives with PCR. Nature 1989 339 :237 8.
15. Gosalvez J Rodriguez-Iñigo E Ramiro-Diaz JL, et al. Relative quantification and mapping of hepatitis C virus by in situ hybridization and digital image analysis. Hepatology 1998 27 :1428 34.
16. Agresti A Coull BA. Approximate is better than ''Exact'' for interval estimation of binomial proportions. Am Stat 1998 52 :119 26.
17. Castillo I Bartolomé J Navas S Gonzalez S Herrero M Carreno V. Virological and biochemical long-term follow-up of patients with chronic hepatitis C treated with interferon. Hepatology 1994 19 :1342 6.
18. Kusaka S Okusa T Araki A, et al. Prediction of relapses after interferon-alpha therapy by hepatitis C virus RNA in peripheral blood mononuclear cells. J Med Virol 1995 46 :265 8.
19. Manns MP McHutchison JG Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 :958 65.
20. Pawlotsky JM Bouvier-Alias M Hezode C Darthuy F Remire J Dhumeaux D. Standardization of hepatitis C virus RNA quantification. Hepatology 2000 32 :654 9.
21. Radkowski M Gallegos-Orozco JF Jablonska J, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005 41 :106 14.
22. Pham TN MacParland SA Mulrooney PM Cooksley H Naoumov NV Michalak TI. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 2004 78 :5867 74.
23. Lee WM Polson JE Carney S Sahin B Gale M. Reemergence of hepatitis C virus after 8.5 years in a patient with hypogammaglobulinemia: evidence for an occult viral reservoir. J Infect Dis 2005 192 :1088 92.